Allergy Therapeutics plc

As of December 31, 2025, Allergy Therapeutics plc carries a market capitalization of 67.56B, placing it among publicly traded companies globally. Its enterprise value stands at 69.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Allergy Therapeutics plc has 6.14B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Allergy Therapeutics plc maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Allergy Therapeutics plc's stock has declined approximately 43.04% over the past 52 weeks. The 50-day moving average sits at 4.98, while the 200-day moving average is 8.30.

As of December 31, 2025, Allergy Therapeutics plc holds 1.01B in cash and equivalents against 2.68B in total debt, resulting in a net debt position of 1.01B. Total book value stands at 424.90M, with working capital of 422.20M providing operational flexibility.

Allergy Therapeutics plc's most recent stock split took place on September 28, 2023 with a 29:63 split ratio.